EA201070657A1 - Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина - Google Patents

Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина

Info

Publication number
EA201070657A1
EA201070657A1 EA201070657A EA201070657A EA201070657A1 EA 201070657 A1 EA201070657 A1 EA 201070657A1 EA 201070657 A EA201070657 A EA 201070657A EA 201070657 A EA201070657 A EA 201070657A EA 201070657 A1 EA201070657 A1 EA 201070657A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fumagillin
methods
bio
compatible
conjugates
Prior art date
Application number
EA201070657A
Other languages
English (en)
Other versions
EA020251B1 (ru
Inventor
Лора К. Экаллиан
Расселл К. Петтер
Джон Дж. Кейн
Чарльз Э. Хаммонд
Мао Йин
Александр Юрковетский
Чери А. Стивенсон
Original Assignee
Мерсана Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерсана Терапьютикс, Инк. filed Critical Мерсана Терапьютикс, Инк.
Publication of EA201070657A1 publication Critical patent/EA201070657A1/ru
Publication of EA020251B1 publication Critical patent/EA020251B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Предложены конъюгаты аналогов фумагиллина с полимерами, способы получения конъюгатов аналогов фумагиллина с полимерами, композиции, содержащие конъюгат аналога фумагиллина с полимером, и способы лечения рака или лечения ангиогенного заболевания, включающие введение субъекту эффективного количества конъюгата аналога фумагиллина с полимером. Также описаны новые аналоги фумагиллина, способы получения аналогов фумагиллина и способы лечения рака или лечения ангиогенного заболевания, включающие введение субъекту, нуждающемуся в этом, эффективного количества аналога фумагиллина.
EA201070657A 2007-11-28 2008-11-24 Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина EA020251B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US458207P 2007-11-28 2007-11-28
PCT/US2008/084539 WO2009073445A2 (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates

Publications (2)

Publication Number Publication Date
EA201070657A1 true EA201070657A1 (ru) 2010-12-30
EA020251B1 EA020251B1 (ru) 2014-09-30

Family

ID=40600044

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070657A EA020251B1 (ru) 2007-11-28 2008-11-24 Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина

Country Status (13)

Country Link
US (2) US8399512B2 (ru)
EP (1) EP2217283A2 (ru)
JP (1) JP5557746B2 (ru)
CN (1) CN101990441A (ru)
AU (1) AU2008331516B2 (ru)
BR (1) BRPI0820229A2 (ru)
CA (1) CA2706914A1 (ru)
EA (1) EA020251B1 (ru)
IL (1) IL206057A0 (ru)
MX (1) MX2010005857A (ru)
NZ (2) NZ585547A (ru)
WO (1) WO2009073445A2 (ru)
ZA (1) ZA201003819B (ru)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667726B1 (en) 2003-09-05 2011-05-04 The General Hospital Corporation Polyacetal drug conjugates as release system
JP5557746B2 (ja) 2007-11-28 2014-07-23 メルサナ セラピューティックス，インク． 生体適合性生分解性フマギリンアナログ複合体
AU2009270799B2 (en) 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
PE20100746A1 (es) * 2008-12-10 2010-11-04 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables
AU2010254013A1 (en) * 2009-05-28 2011-11-24 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
CN102639494B (zh) 2009-10-09 2016-11-09 扎夫根公司 砜化合物及其制备和使用方法
KR101696960B1 (ko) 2010-01-08 2017-01-16 자프겐 인크. 푸마길롤 타입 화합물 및 그의 제조 및 사용 방법
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US9320805B2 (en) 2010-05-25 2016-04-26 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
EA029941B1 (ru) 2010-11-09 2018-06-29 Зафджен, Инк. Фармацевтическая композиция на основе кристаллической формы ингибитора metap-2 и способ лечения ожирения
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン，インコーポレイテッド ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
CA2829204C (en) 2011-03-08 2019-12-24 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
JP6035327B2 (ja) 2011-05-06 2016-11-30 ザフゲン，インコーポレイテッド 三環式ピラゾールスルホンアミド化合物ならびにその製造および使用方法
BR112013031819B1 (pt) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
IN2014MN01488A (ru) * 2011-12-23 2015-04-17 Mersana Therapeutics Inc
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
EP2804856B1 (en) 2012-01-18 2017-03-15 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
MX2014013599A (es) 2012-05-08 2015-05-11 Zafgen Inc Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
MX356755B (es) 2012-05-09 2018-06-11 Zafgen Inc Compuestos de tipo fumagilol y metodos para su elaboración y uso.
WO2014071368A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Methods of treating liver diseases
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
AU2014236528A1 (en) 2013-03-14 2015-09-24 Zafgen, Inc. Methods of treating renal disease and other disorders
MX371095B (es) 2013-04-10 2020-01-16 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6427564B2 (ja) 2013-10-11 2018-11-21 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー タンパク質−ポリマー−薬物共役体
JP6493868B2 (ja) * 2014-09-24 2019-04-03 日東電工株式会社 ジグリコールアミド酸型配位子を有するビニルモノマー
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
SG11201704710PA (en) 2014-12-09 2017-07-28 Abbvie Inc Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
CN107249643A (zh) 2014-12-09 2017-10-13 艾伯维公司 具有细胞渗透性的bcl‑xl抑制剂的抗体药物缀合物
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) * 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
AU2016365117A1 (en) 2015-11-30 2018-05-31 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
JP2019500327A (ja) 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
JP2019501898A (ja) 2015-12-10 2019-01-24 シンデブルックス，インコーポレイティド フマギロール誘導体およびその多形体
KR20180100663A (ko) 2016-01-11 2018-09-11 신데브알엑스, 인크. 대사 기능장애에 의하여 유도된 종양에 대한 치료
CA3018081A1 (en) 2016-03-22 2017-09-28 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
US20170348429A1 (en) 2016-05-17 2017-12-07 Abbvie Biotherapeutics Inc. ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
JP2019524649A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
US20190153108A1 (en) 2016-06-08 2019-05-23 Abbvie Inc. Anti-egfr antibody drug conjugates
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
CA3027046A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
TW202320860A (zh) 2016-06-08 2023-06-01 美商艾伯維有限公司 抗egfr抗體藥物結合物
BR112018075653A2 (pt) 2016-06-08 2019-08-27 Abbvie Inc anticorpos anti-b7-h3 e conjugados anticorpo fármaco
US20190153107A1 (en) 2016-06-08 2019-05-23 Abbvie Inc. Anti-egfr antibody drug conjugates
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
JP2019527716A (ja) * 2016-08-11 2019-10-03 ザフゲン，インコーポレイテッド フマギロール化合物ならびにその製造方法および使用方法
MX2019004690A (es) 2016-10-19 2019-09-27 Invenra Inc Constructos de anticuerpos.
MX2019007019A (es) 2016-12-22 2019-08-16 Univ Degli Studi Magna Graecia Catanzaro Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
CN106831662B (zh) * 2016-12-29 2018-12-18 中国农业科学院蜜蜂研究所 一种胺基多元醇代烟曲霉素及其合成方法与应用
EP3641826B1 (en) 2017-06-22 2023-12-06 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
WO2019118612A1 (en) * 2017-12-12 2019-06-20 Zafgen, Inc. Targeting compounds
CR20200571A (es) 2018-06-01 2021-01-18 Novartis Ag Moléculas de únion contra bcma y usos de las mismas
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
CN113453721A (zh) 2018-10-26 2021-09-28 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
AU2020327000A1 (en) 2019-08-08 2022-03-31 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
JP2022553830A (ja) 2019-11-05 2022-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｎ末端ｓｃＦｖ多重特異性結合分子
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN115315446A (zh) 2020-03-06 2022-11-08 Go医疗股份有限公司 抗糖-cd44抗体及其用途
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
AU2022324456A1 (en) 2021-08-05 2024-02-15 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
CA3230933A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023156996A1 (en) * 2022-02-16 2023-08-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metap2 inhibitors and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) * 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
US5164410A (en) * 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
KR0138530B1 (ko) * 1988-09-01 1998-05-15 우메모또 요시마사 푸마길롤 유도체
US5180738A (en) * 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
JP2858724B2 (ja) * 1988-09-01 1999-02-17 武田薬品工業株式会社 血管新生阻害剤
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
ATE153854T1 (de) * 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd Stabile pharmazeutische zubereitung mit fumagillolderivaten
EA000150B1 (ru) * 1995-03-27 1998-10-29 Санофи Применение фумагиллола и его производных для приготовления лекарств, предназначенных для борьбы с кишечными инфекциями, и фармацевтическая композиция на их основе
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
WO1999061432A1 (en) 1998-05-12 1999-12-02 Biochem Pharma Inc. Fumagillin analogs and their use as angiogenesis inhibitors
KR100357541B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
US6603812B1 (en) * 1998-08-17 2003-08-05 Linear Technology Corporation Hardware implementation of a decimating finite impulse response filter
AU6409499A (en) * 1998-10-01 2000-04-17 Children's Medical Center Corporation Method of treatment of cardiovascular injuries
PT1156829E (pt) * 1999-02-26 2007-08-17 Sanofi Aventis ''formulação estável contendo fumagilina''
HUP9901943A2 (hu) * 1999-06-11 2001-12-28 Sanofi-Synthelabo Eljárás fumagillin előállítására
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
GB0012179D0 (en) * 2000-05-20 2000-07-12 Imp Cancer Res Tech Assays and drug screening systems
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
WO2002042295A2 (en) * 2000-11-01 2002-05-30 Praecis Pharmaceuticals Inc. Peptides as met-ap2 inhibitors
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) * 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1436286B1 (en) * 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
US6803382B2 (en) * 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
US7838619B2 (en) * 2002-01-14 2010-11-23 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
DE60329126D1 (de) * 2002-02-20 2009-10-15 Beth Israel Hospital Konjugate mit biologisch abbaubarem polymer und verwendung dafür
CA2480666C (en) * 2002-04-11 2012-03-06 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
WO2004009774A2 (en) * 2002-07-19 2004-01-29 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
US8030459B2 (en) * 2002-07-19 2011-10-04 The General Hospital Corporation Oxime conjugates and methods for their formation and use
EP1667726B1 (en) * 2003-09-05 2011-05-04 The General Hospital Corporation Polyacetal drug conjugates as release system
FR2872511B1 (fr) * 2004-06-30 2006-08-11 Galderma Res & Dev Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
AU2006247471A1 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
US8110572B2 (en) * 2007-07-16 2012-02-07 Abbott Laboratories Inhibitors of protein kinases
JP5557746B2 (ja) 2007-11-28 2014-07-23 メルサナ セラピューティックス，インク． 生体適合性生分解性フマギリンアナログ複合体
AU2010254013A1 (en) * 2009-05-28 2011-11-24 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers

Also Published As

Publication number Publication date
US20090148396A1 (en) 2009-06-11
IL206057A0 (en) 2010-11-30
US8399512B2 (en) 2013-03-19
WO2009073445A2 (en) 2009-06-11
EA020251B1 (ru) 2014-09-30
US20130158046A1 (en) 2013-06-20
BRPI0820229A2 (pt) 2017-05-09
JP5557746B2 (ja) 2014-07-23
CN101990441A (zh) 2011-03-23
AU2008331516B2 (en) 2014-01-09
AU2008331516A1 (en) 2009-06-11
JP2011504964A (ja) 2011-02-17
NZ585547A (en) 2012-12-21
ZA201003819B (en) 2013-09-25
CA2706914A1 (en) 2009-06-11
EP2217283A2 (en) 2010-08-18
WO2009073445A3 (en) 2010-01-28
MX2010005857A (es) 2010-11-22
NZ600039A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
EA201070657A1 (ru) Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
CY1121134T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης
CY1120807T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
IN2012DN00407A (ru)
CY1118821T1 (el) Γελες με βαση υαλουρονικο οξυ οι οποιες περιλαμβανουν αναισθητικους παραγοντες
CY1120975T1 (el) Συστημα αποθεματος που περιλαμβανει οξικη γλατιραμερη
BRPI0416028B8 (pt) composto, conjugados do composto, composição farmacêutica e usos do conjugado
NZ590569A (en) Factor viii polymer conjugates
EP1988910A4 (en) CONJUGATES OF POLYMERS CONTAINING ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE AND THEIR PREPARATION
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
BR112012012210B8 (pt) conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
MX2008001706A (es) Conjugados de una porcion g-csf y un polimero.
MX2012008603A (es) Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
WO2010123945A3 (en) Silk fibroin hydrogels and uses thereof
MX2011007544A (es) Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
AU2010210593A8 (en) Nanoscale platinum compounds and methods of use thereof
WO2010009111A3 (en) A drug depot implantable within a synovial joint
RU2010137032A (ru) Конъюгаты паклитаксела с полимером и способы лечения рака
DE602005025355D1 (de) Konjugate enthaltend gm-csf und ein polymer
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
PE20130254A1 (es) Factor viii conjugado para coagulacion de la sangre

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU